Institute of Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan.
Department of Molecular Biology and Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
PLoS One. 2023 Oct 26;18(10):e0293194. doi: 10.1371/journal.pone.0293194. eCollection 2023.
Tuberculosis stands as a prominent cause of mortality in developing countries. The treatment of tuberculosis involves a complex procedure requiring the administration of a panel of at least four antimicrobial drugs for the duration of six months. The occurrence of treatment failure after the completion of a standard treatment course presents a serious medical problem. The purpose of this study was to evaluate antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. Additionally, it aimed to evaluate the effectiveness of second line drugs such as amikacin, linezolid, moxifloxacin, and the efflux pump inhibitor verapamil against M. tuberculosis isolates associated with treatment failure. We monitored 1200 tuberculosis patients who visited TB centres in Lahore and found that 64 of them were not cured after six months of treatment. Among the M. tuberculosis isolates recovered from the sputum of these 64 patients, 46 (71.9%) isolates were simultaneously resistant to rifampicin and isoniazid (MDR), and 30 (46.9%) isolates were resistant to pyrazinamide, Resistance to amikacin was detected in 17 (26,5%) isolates whereas resistance to moxifloxacin and linezolid was detected in 1 (1.5%) and 2 (3.1%) isolates respectively. Among MDR isolates, the additional resistance to pyrazinamide, amikacin, and linezolid was detected in 15(23.4%), 4(2.6%) and 1(1.56%) isolates respectively. One isolate simultaneously resistant to rifampicin, isoniazid, amikacin, pyrazinamide, and linezolid was also identified. In our investigations, the most frequently mutated amino acid in the treatment failure group was Serine 315 in katG. Three novel mutations were detected at codons 99, 149 and 154 in pncA which were associated with pyrazinamide resistance. The effect of verapamil on the minimum inhibitory concentration of isoniazid and rifampicin was observed in drug susceptible isolates but not in drug resistant isolates. Rifampicin and isoniazid enhanced the transcription of the efflux pump gene rv1258 in drug susceptible isolates collected from the treatment failure patients. Our findings emphasize a high prevalence of MDR isolates linked primarily to drug exposure. Moreover, the use of amikacin as a second line drug may not be the most suitable choice in such cases.
结核病是发展中国家主要的死亡原因之一。结核病的治疗涉及一个复杂的过程,需要至少四种抗菌药物联合治疗 6 个月。在标准疗程完成后出现治疗失败是一个严重的医学问题。本研究旨在评估与治疗失败相关的结核分枝杆菌的抗微生物药物耐药特征。此外,还评估了阿米卡星、利奈唑胺、莫西沙星和外排泵抑制剂维拉帕米等二线药物对与治疗失败相关的结核分枝杆菌分离株的疗效。我们监测了 1200 名在拉合尔结核病中心就诊的结核病患者,发现其中 64 名患者在 6 个月的治疗后未痊愈。在从这 64 名患者的痰液中分离出的结核分枝杆菌中,46 株(71.9%)同时对利福平异烟肼(MDR)耐药,30 株(46.9%)对吡嗪酰胺耐药。17 株(26.5%)对阿米卡星耐药,1 株(1.5%)和 2 株(3.1%)对莫西沙星和利奈唑胺耐药。在 MDR 分离株中,15 株(23.4%)、4 株(2.6%)和 1 株(1.56%)对吡嗪酰胺、阿米卡星和利奈唑胺的额外耐药性。还鉴定出一株同时对利福平、异烟肼、阿米卡星、吡嗪酰胺和利奈唑胺耐药的分离株。在我们的研究中,治疗失败组中最常见的突变氨基酸是 katG 中的丝氨酸 315。在 pncA 中检测到三个新的突变,位于密码子 99、149 和 154,与吡嗪酰胺耐药有关。在敏感株中观察到维拉帕米对异烟肼和利福平最低抑菌浓度的影响,但在耐药株中未观察到。在从治疗失败患者中收集的敏感分离株中,利福平和异烟肼增强了外排泵基因 rv1258 的转录。我们的研究结果强调了主要与药物暴露相关的 MDR 分离株的高流行率。此外,在这种情况下,阿米卡星作为二线药物的使用可能不是最佳选择。